Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma: HELP
Articles by A. Berrocal
Based on 5 articles published since 2008
||||

Between 2008 and 2019, A. Berrocal wrote the following 5 articles about Melanoma.
 
+ Citations + Abstracts
1 Guideline SEOM clinical guideline for the management of malignant melanoma (2017). 2018

Berrocal, A / Arance, A / Castellon, V E / de la Cruz, L / Espinosa, E / Cao, M G / Larriba, J L G / Márquez-Rodas, I / Soria, A / Algarra, S M. ·Servicio de Oncología Médica, Consorcio Hospital General Universitario de Valencia, Avda. Tres Cruces 2, 46014, Valencia, Spain. berrocal.alf@gmail.com. · Hospital Clinic I Provincial de Barcelona, Barcelona, Spain. · Hospital Torrecárdenas, Almería, Spain. · Complejo Hospitalario Regional Virgen Macaren, Seville, Spain. · Hospital Universitario la Paz, Madrid, Spain. · Hospital Universitario Quirón Dexeus, Barcelona, Spain. · Hospital Universitario Clínico San Carlos, Madrid, Spain. · Hospital General Universitario Gregorio Marañón, Madrid, Spain. · Hospital Universitario Ramón y Cajal, Madrid, Spain. · Clínica Universitaria de Navarra, Pamplona, Spain. ·Clin Transl Oncol · Pubmed #29116432.

ABSTRACT: All melanoma suspected patients must be confirmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon could be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 containing therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 containing therapy. Up to 10 years follow up is reasonable for melanoma patients with dermatologic examinations and physical exams.

2 Guideline Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. 2014

Martín-Algarra, S / Fernández-Figueras, M T / López-Martín, J A / Santos-Briz, A / Arance, A / Lozano, M D / Berrocal, A / Ríos-Martín, J J / Espinosa, E / Rodríguez-Peralto, J L / Anonymous3550772 / Anonymous3560772. ·Medical Oncology Department, Clínica Universidad de Navarra, Avenida de Pio XII, 36, 31008, Pamplona, Spain, smalgarra@unav.es. ·Clin Transl Oncol · Pubmed #24129426.

ABSTRACT: This consensus statement, conceived as a joint initiative of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM), makes diagnostic and treatment recommendations for the management of patients with advanced or metastatic melanoma based on the current scientific evidence on biomarker use. This document thus provides an opportunity to improve healthcare efficiency and resource use, which will benefit these patients. Based on the data available so far, this expert group recommends routinely testing patients with metastatic melanoma for BRAF mutation status, as the result affects the subsequent therapeutic management of these patients. The analysis of genetic alterations in KIT may be reasonable in patients with primary tumours in acral or mucosal sites or on chronically sun-exposed skin, in an advanced condition, but not in patients with other types of melanomas. This panel believes that testing for other genetic alterations, such as NRAS mutation status in patients not carrying BRAF mutations, GNAQ/GNA11 mutational analysis or genetic alterations in PTEN, is not currently indicated as routine clinical practice, because the results do not influence treatment planning in these patients at the present time. Other important issues addressed in this document are the organisational requirements and quality controls needed for proper testing of these biomarkers, and the legal implications to be borne in mind.

3 Clinical Trial Safety of vemurafenib in patients with BRAF 2016

Arance, A M / Berrocal, A / Lopez-Martin, J A / de la Cruz-Merino, L / Soriano, V / Martín Algarra, S / Alonso, L / Cerezuela, P / La Orden, B / Espinosa, E. ·Hospital Clínic and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. AMARANCE@clinic.ub.es. · Hospital General Universitario de Valencia, Valencia, Spain. · Hospital Universitario 12 de Octubre, Madrid, Spain. · Hospital Univ. Virgen de la Macarena de Sevilla, Seville, Spain. · Instituto Valenciano de Oncología, Valencia, Spain. · Clínica Universidad de Navarra, Navarra, Spain. · Hospital Clínico de Málaga, Malaga, Spain. · Hospital Universitario Santa Lucía de Cartagena, Cartagena, Spain. · Roche Farma, Madrid, Spain. · Hospital Universitario La Paz, Madrid, Spain. ·Clin Transl Oncol · Pubmed #26983408.

ABSTRACT: OBJECTIVES: Vemurafenib tolerability was assessed in a large, open-label, multicentre study in patients with BRAF METHODS: Patients with previously treated or treatment-naive, unresectable stage IIIC or stage IV, BRAF RESULTS: 301 Spanish patients were included, 70 % with M1c disease, 22 % with brain metastases and 51 % with prior systemic therapy for metastatic disease. Most frequent adverse events included fatigue (48 %), arthralgia (45 %), rash (41 %), photosensitivity (34 %) and skin neoplasms (21 %). Grade 3/4 adverse events occurred in 156 patients (52 %), including cutaneous squamous cell carcinoma (including keratoacanthoma; 16 %), fatigue (6 %) and arthralgia (5 %). The ORR was 28 % (95 % CI 23-34 %). Responses occurred in patients with brain metastases (18 %), elevated baseline lactate dehydrogenase (19 %) and poor performance status (15 %), and elderly patients (22 %). Median PFS was 5.8 (95 % CI 5.0-6.4) months; median OS was 10.5 (95 % CI 9.5-13.5) months. CONCLUSION: Our results for Spanish patients in the vemurafenib safety study indicate similar efficacy and a comparable safety profile in Spanish patients with no new safety signals compared with the overall population. Clinical benefit was demonstrated in poor-prognosis patients and in those with favourable baseline characteristics, suggesting that poor-prognosis patients may also benefit from vemurafenib treatment.

4 Article Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program. 2017

González-Cao, M / Arance, A / Piulats, J M / Marquez-Rodas, I / Manzano, J L / Berrocal, A / Crespo, G / Rodriguez, D / Perez-Ruiz, E / Berciano, M / Soria, A / Castano, A G / Espinosa, E / Montagut, C / Alonso, L / Puertolas, T / Aguado, C / Royo, M A / Blanco, R / Rodríguez, J F / Muñoz, E / Mut, P / Barron, F / Martin-Algarra, S / Anonymous4770892. ·Translational Cancer Research Unit, Dr. Rosell Oncology Institute, Quiron Dexeus University Hospital, 08028, Barcelona, Spain. mgonzalezcao@oncorosell.com. · Hospital Clinic I Provincial, Barcelona, Spain. · Catalan Institute of Oncology, Barcelona, Spain. · Gregorio Marañón Institute of Health Research, Madrid, Spain. · Germans Trias I Pujol University Hospital, Barcelona, Spain. · General University Hospital, Valencia, Spain. · Burgos University Hospital, Burgos, Spain. · Insular University Hospital of Gran Canaria, Canary Islands, Spain. · Costa del Sol Hospital, Marbella, Malaga, Spain. · Regional University Hospital of Malaga, Malaga, Spain. · Ramony Cajal Hospital, Madrid, Spain. · Marqués de Valdecilla University Hospital, Santander, Spain. · La Paz University Hospital, Madrid, Spain. · Del Mar University Hospital, Barcelona, Spain. · Virgen de la Victoria Hospital, Malaga, Spain. · Miguel Servet University Hospital, Zaragoza, Spain. · San Carlos Hospital, Madrid, Spain. · Dr. Peset Hospital, Valencia, Spain. · Consorci Sanitari de Terrassa, Barcelona, Spain. · Clara Campal Hospital, Madrid, Spain. · Valld'Hebron University Hospital, Barcelona, Spain. · Son Llatzer University Hospital, Mallorca, Spain. · National Cancer Institute, Mexico City, Mexico. · Navarra University Clinic, Pamplona, Spain. ·Clin Transl Oncol · Pubmed #28054320.

ABSTRACT: BACKGROUND: The programmed death (PD-1) inhibitor pembrolizumab has been recently approved for the treatment of advanced melanoma. We evaluated the clinical activity of pembrolizumab in melanoma patients treated under the Spanish Expanded Access Program. METHODS: Advanced melanoma patients who failed to previous treatment lines were treated with pembrolizumab 2 mg/kg every three weeks. Patients with brain metastases were not excluded if they were asymptomatic. Data were retrospectively collected from 21 centers in the Spanish Melanoma Group. RESULTS: Sixty-seven advanced melanoma patients were analyzed. Most patients were stage M1c (73.1%), had high LDH levels (55.2%) and had ECOG PS 1 or higher (59.7%). For cutaneous melanoma patients, median overall survival was 14.0 months; the 18-month overall survival rate was 47.1%. Overall response rate was 27%, including three patients with complete responses (6.5%). Median response duration was not reached, with 83.3% of responses ongoing (3.5 m+ to 20.4 m+). From ten patients included with brain metastases, four (40%) had an objective response, two (20%) of them achieved a complete response. Significant prognostic factors for overall survival were LDH level, ECOG PS and objective response. There were no serious adverse events. CONCLUSION: Although this was a heavily pretreated cohort, pembrolizumab activity at the approved dose and schedule was confirmed in the clinical setting with long-term responders, also including patients with brain metastases.

5 Article SEOM guidelines for the management of Malignant Melanoma 2015. 2015

Berrocal, A / Arance, A / Espinosa, E / Castaño, A G / Cao, M G / Larriba, J L G / Martín, J A L / Márquez, I / Soria, A / Algarra, S M. ·Servicio de Oncología Médica, Consorcio Hospital General Universitario de Valencia, Avda. Tres Cruces 2, 46014, Valencia, Spain. berrocal.alf@gmail.com. · Hospital Clinic I Provincial de Barcelona, Barcelona, Spain. · Hospital Universitario la Paz, Madrid, Spain. · Hospital Universitario Marqués de Valdecilla, Santander, Spain. · Hospital Universitario Quirón Dexeus, Barcelona, Spain. · Hospital Universitario Clínico San Carlos, Madrid, Spain. · Hospital Universitario 12 de Octubre, Madrid, Spain. · Hospital General Universitario Gregorio Marañón, Madrid, Spain. · Hospital Universitario Ramón y Cajal, Madrid, Spain. · Clínica Universitaria de Navarra, Pamplona, Spain. ·Clin Transl Oncol · Pubmed #26669314.

ABSTRACT: All melanoma patients must be confirmed histologically and resected according to Breslow. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon must be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 therapy. Up to 10 years follow up is recommended for melanoma patients with dermatologic examinations and physical exams.